Retrospective Analysis to Characterize the Real World Use Patterns, Efficacy and Safety of Ceftazidime-avibactam in the Management of Gram Negative Infections
Latest Information Update: 16 Aug 2024
Price :
$35 *
At a glance
- Drugs Avibactam/ceftazidime (Primary)
- Indications Gram-negative infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 09 Nov 2022 Status changed from active, no longer recruiting to completed.
- 22 Jun 2022 Planned End Date changed from 28 Feb 2022 to 31 Jul 2022.
- 22 Jun 2022 Planned primary completion date changed from 28 Feb 2022 to 31 Jul 2022.